Filing Details

Accession Number:
0001387131-23-001468
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-02-06 16:18:12
Reporting Period:
2021-08-12
Accepted Time:
2023-02-06 16:18:12
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1570562 Evolus Inc. EOLS Pharmaceutical Preparations (2834) 461385614
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1848514 Medytox Inc. 78, Gangni 1-Gil, Ochang-Eup,
Cheongwon-Gu
Cheogiu-Si M5 28126
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.00001 Par Value Per Share Acquisiton 2021-08-12 23,000 $10.99 7,282,500 No 4 P Indirect See Footnote
Common Stock, $0.00001 Par Value Per Share Acquisiton 2021-08-13 14,043 $11.11 7,296,543 No 4 P Indirect See Footnote
Common Stock, $0.00001 Par Value Per Share Disposition 2023-01-20 37,043 $11.04 7,259,500 No 4 S Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
No 4 S Indirect See Footnote
Footnotes
  1. Inadvertently filed late due to an administrative error.
  2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.88 to $11.10, inclusive. The reporting person undertakes to provide to Evolus, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes 1 to 2.
  3. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.91 to $11.26, inclusive.
  4. The Issuer shares were previously held of record by Medytox Korea Co., Ltd. ("Medytox Korea"). Medytox, Inc. owns 100% of Medytox Korea. Accordingly, Medytox, Inc. may be deemed to beneficially own indirectly the shares by reason of Medytox Korea's direct beneficial ownership.